• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

The American Diabetes Association (ADA)“Standards of Care in Diabetes” includes the
ADA's current clinical practice recommendations and is intended to provide the components …

Background Semaglutide, a glucagon-like peptide-1 receptor agonist, has been shown to
reduce the risk of adverse cardiovascular events in patients with diabetes. Whether …

The effects of tirzepatide, a glucose-dependent insulinotropic polypeptide and glucagon-like
peptide-1 receptor agonist, on weight reduction after successful intensive lifestyle …

Enormous progress has been made in the last half-century in the management of diseases
closely integrated with excess body weight, such as hypertension, adult-onset diabetes and …

The accumulation of an excessive amount of body fat can cause type 2 diabetes, and the
risk of type 2 diabetes increases linearly with an increase in body mass index. Accordingly …

Objective The objective of this clinical practice guideline is to provide updated and new
evidence-based recommendations for the comprehensive care of persons with diabetes …

1. Specific recommendations for prevention strategies often depend on the ischemic
stroke/transient ischemic attack subtype. Therefore, new in this guideline is a section …

Background Pharmacotherapy provides an option for adults with overweight and obesity to
reduce their bodyweight if lifestyle modifications fail. We summarised the latest evidence for …

Background This trial assessed the efficacy and safety of the GLP-1 analogue once a week
subcutaneous semaglutide 2· 4 mg versus semaglutide 1· 0 mg (the dose approved for …